SI3539540T1 - Inhibitor SGLT2 1-kloro-4-(beta-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran- 3-iloksi)-benzil]-benzen v kombinaciji z insulinom za uporabo pri postopku za zmanjšanje tveganja hipoglikemije - Google Patents

Inhibitor SGLT2 1-kloro-4-(beta-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran- 3-iloksi)-benzil]-benzen v kombinaciji z insulinom za uporabo pri postopku za zmanjšanje tveganja hipoglikemije

Info

Publication number: SI3539540T1
Authority: SI; Slovenia
Prior art keywords: glucopyranos; hypoglycemia; yloxy; insulin; tetrahydrofuran
Prior art date: 2010-11-08

Application number

SI201132125T

Other languages

English (en)

Inventor

Rolf Grempler

Odd-Erik Johansen

Thomas Klein

Gerd Luippold

Michael Mark

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-08

Filing date

2011-11-07

Publication date

2025-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3539540(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-07 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2025-03-31 Publication of SI3539540T1 publication Critical patent/SI3539540T1/sl

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
YZGOOQZXQOPQNT-DNNBANOASA-N (2r,3r,4s,5s,6r)-2-[4-chloro-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 YZGOOQZXQOPQNT-DNNBANOASA-N 0.000 title 1
208000013016 Hypoglycemia Diseases 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title 1
230000002218 hypoglycaemic effect Effects 0.000 title 1
229940125396 insulin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)

SI201132125T 2010-11-08 2011-11-07 Inhibitor SGLT2 1-kloro-4-(beta-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran- 3-iloksi)-benzil]-benzen v kombinaciji z insulinom za uporabo pri postopku za zmanjšanje tveganja hipoglikemije SI3539540T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10190303		2010-11-08
EP11151059		2011-01-17
EP19163940.0A EP3539540B1 (en)	2010-11-08	2011-11-07	Sglt2 inhibitor 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3- yloxy)-benzyl]-benzene in combination with insulin for use in a method for reducing the risk of hypoglycemia

Publications (1)

Publication Number	Publication Date
SI3539540T1 true SI3539540T1 (sl)	2025-03-31

Family

ID=44906182

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201132125T SI3539540T1 (sl)	2010-11-08	2011-11-07	Inhibitor SGLT2 1-kloro-4-(beta-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran- 3-iloksi)-benzil]-benzen v kombinaciji z insulinom za uporabo pri postopku za zmanjšanje tveganja hipoglikemije

Country Status (31)

Country	Link
US (6)	US20120283169A1 (sl)
EP (2)	EP3539540B1 (sl)
JP (3)	JP2013541576A (sl)
KR (3)	KR102051285B1 (sl)
CN (2)	CN103282030A (sl)
AP (1)	AP2013006813A0 (sl)
AR (1)	AR083787A1 (sl)
AU (1)	AU2011328231B2 (sl)
BR (1)	BR112013011968A2 (sl)
CA (1)	CA2813661C (sl)
CL (1)	CL2013001104A1 (sl)
CO (1)	CO6781465A2 (sl)
DK (1)	DK3539540T3 (sl)
EA (1)	EA026712B1 (sl)
EC (1)	ECSP13012661A (sl)
ES (1)	ES3012504T3 (sl)
FI (1)	FI3539540T3 (sl)
HR (1)	HRP20250096T1 (sl)
HU (1)	HUE070541T2 (sl)
IL (1)	IL225597A0 (sl)
LT (1)	LT3539540T (sl)
MA (1)	MA34640B1 (sl)
MX (2)	MX374694B (sl)
NZ (1)	NZ608829A (sl)
PE (1)	PE20140244A1 (sl)
PH (2)	PH12013500809A1 (sl)
PL (1)	PL3539540T3 (sl)
RS (1)	RS66479B1 (sl)
SG (1)	SG189249A1 (sl)
SI (1)	SI3539540T1 (sl)
WO (1)	WO2012062698A1 (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
SG173619A1 (en)	2009-02-13	2011-09-29	Boehringer Ingelheim Int	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EA020798B1 (ru)	2009-09-30	2015-01-30	Бёрингер Ингельхайм Интернациональ Гмбх	СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
WO2011039108A2 (en)	2009-09-30	2011-04-07	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
FI2981269T3 (fi)	2013-04-04	2023-09-27	Boehringer Ingelheim Vetmedica Gmbh	Aineenvaihduntahäiriöiden hoito hevoseläimillä
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) *	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt)	2013-04-05	2019-02-19	Boehringer Ingelheim Int	Utilizações terapêuticas de empagliflozina
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
SI2986304T1 (sl)	2013-04-18	2022-04-29	Boehringer Ingelheim International Gmbh	Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
RS64990B1 (sr) *	2013-12-17	2024-01-31	Boehringer Ingelheim Vetmedica Gmbh	Sglt-2 inhibitor za primenu u lečenju metaboličkog poremećaja kod životinja iz roda mačaka
EA201891406A1 (ru) *	2014-01-23	2018-12-28	Бёрингер Ингельхайм Ветмедика Гмбх	Лечение метаболических расстройств у представителей собачьих
NZ723781A (en)	2014-04-01	2022-09-30	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in equine animals
US10555958B2 (en)	2014-09-25	2020-02-11	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN104473920A (zh) *	2014-12-20	2015-04-01	长沙佰顺生物科技有限公司	一种用于治疗2型糖尿病的复方制剂及其制备方法
ES2999279T3 (en)	2015-08-27	2025-02-25	Boehringer Ingelheim Vetmedica Gmbh	Liquid pharmaceutical compositions comprising sglt-2 inhibitors
CN109922813A (zh)	2016-11-10	2019-06-21	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
CN110092768A (zh) *	2018-04-23	2019-08-06	中国科学院成都生物研究所	包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法
US20220257626A1 (en) *	2019-07-23	2022-08-18	Novartis Ag	Treatment comprising sglt inhibitors
CN110327355B (zh) *	2019-08-12	2021-06-04	浙江养生堂天然药物研究所有限公司	包含柠檬苦素类化合物和sglt-2抑制剂的组合产品
WO2021046325A1 (en) *	2019-09-04	2021-03-11	The Regents Of The University Of Michigan	Inhibitors of sglt and uses thereof
US20210093698A1 (en) *	2019-09-13	2021-04-01	Sanofi	Treatment of type 2 diabetes mellitus
WO2025007870A1 (zh) *	2023-07-04	2025-01-09	连云港市瓦尔生物医药科技有限公司	一种控制血糖的药物组合试剂盒

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100591585B1 (ko)	1999-08-31	2006-06-20	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US7053060B2 (en)	2000-11-30	2006-05-30	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
RU2317302C2 (ru)	2000-12-28	2008-02-20	Киссеи Фармасьютикал Ко., Лтд.	Производные глюкопиранозилоксипиразола и их применение в лекарственных средствах
MXPA04009229A (es)	2002-03-22	2004-11-26	Kissei Pharmaceutical	Cristales derivados de glucopiranosiloxibencil benceno.
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4222450B2 (ja)	2003-03-14	2009-02-12	アステラス製薬株式会社	Ｃ−グリコシド誘導体又はその塩
RS53365B (sr)	2003-08-01	2014-10-31	Mitsubishi Tanabe Pharma Corporation	Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
DE102004012676A1 (de) *	2004-03-16	2005-10-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN103467423B (zh)	2004-03-16	2016-03-16	贝林格尔.英格海姆国际有限公司	吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1828216B1 (en)	2004-12-16	2008-09-10	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP5175191B2 (ja)	2005-08-30	2013-04-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
WO2007028814A1 (en)	2005-09-08	2007-03-15	Boehringer Ingelheim International Gmbh	CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
AR056195A1 (es)	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
ATE517099T1 (de)	2006-02-15	2011-08-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
TWI370818B (en)	2006-04-05	2012-08-21	Astellas Pharma Inc	Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7803778B2 (en)	2006-05-23	2010-09-28	Theracos, Inc.	Glucose transport inhibitors and methods of use
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
TWI403516B (zh)	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
WO2008020011A1 (en)	2006-08-15	2008-02-21	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
JP2010507629A (ja)	2006-10-27	2010-03-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
TW200829258A (en)	2006-11-06	2008-07-16	Boehringer Ingelheim Int	Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
UA100008C2 (ru) *	2006-11-09	2012-11-12	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
PE20090185A1 (es)	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
NO2200606T3 (sl)	2007-09-10	2018-03-24
KR20100111682A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
CN101970476B (zh)	2008-01-09	2014-08-27	塞诺菲-安万特德国有限公司	具有超延迟时效特征的胰岛素衍生物
CN101503399B (zh) *	2008-02-04	2012-06-27	白鹭医药技术（上海）有限公司	C-芳基葡萄糖苷sglt2抑制剂
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
SG173032A1 (en)	2009-02-13	2011-08-29	Boehringer Ingelheim Int	Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
BRPI1013640A2 (pt)	2009-02-13	2019-09-24	Boehringer Ingelheim Int	composicao farmaceutica, metodos para o tratamento e usos dos mesmos
SG2014012462A (en) *	2009-04-16	2014-05-29	Taisho Pharmaceutical Co Ltd	Pharmaceutical compositions
US8685934B2 (en) *	2009-05-27	2014-04-01	Bristol-Myers Squibb Company	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
JP2013523681A (ja) *	2010-03-30	2013-06-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
JP5876170B2 (ja) *	2015-01-13	2016-03-02	株式会社平和	遊技機

2011
- 2011-11-02 US US13/287,216 patent/US20120283169A1/en not_active Abandoned
- 2011-11-07 CA CA2813661A patent/CA2813661C/en active Active
- 2011-11-07 MX MX2018006655A patent/MX374694B/es unknown
- 2011-11-07 KR KR1020187022985A patent/KR102051285B1/ko active Active
- 2011-11-07 LT LTEP19163940.0T patent/LT3539540T/lt unknown
- 2011-11-07 KR KR1020197034873A patent/KR102232451B1/ko active Active
- 2011-11-07 CN CN201180064091XA patent/CN103282030A/zh active Pending
- 2011-11-07 EP EP19163940.0A patent/EP3539540B1/en active Active
- 2011-11-07 PH PH1/2013/500809A patent/PH12013500809A1/en unknown
- 2011-11-07 ES ES19163940T patent/ES3012504T3/es active Active
- 2011-11-07 FI FIEP19163940.0T patent/FI3539540T3/fi active
- 2011-11-07 BR BR112013011968A patent/BR112013011968A2/pt not_active IP Right Cessation
- 2011-11-07 MX MX2013005095A patent/MX356491B/es active IP Right Grant
- 2011-11-07 CN CN201610579791.7A patent/CN106177957A/zh active Pending
- 2011-11-07 HR HRP20250096TT patent/HRP20250096T1/hr unknown
- 2011-11-07 PE PE2013000955A patent/PE20140244A1/es not_active Application Discontinuation
- 2011-11-07 DK DK19163940.0T patent/DK3539540T3/da active
- 2011-11-07 NZ NZ608829A patent/NZ608829A/en unknown
- 2011-11-07 EP EP11778916.4A patent/EP2637648A1/en not_active Withdrawn
- 2011-11-07 AU AU2011328231A patent/AU2011328231B2/en active Active
- 2011-11-07 KR KR1020137011966A patent/KR20130125365A/ko not_active Ceased
- 2011-11-07 HU HUE19163940A patent/HUE070541T2/hu unknown
- 2011-11-07 PL PL19163940.0T patent/PL3539540T3/pl unknown
- 2011-11-07 AP AP2013006813A patent/AP2013006813A0/xx unknown
- 2011-11-07 SI SI201132125T patent/SI3539540T1/sl unknown
- 2011-11-07 JP JP2013537158A patent/JP2013541576A/ja active Pending
- 2011-11-07 WO PCT/EP2011/069532 patent/WO2012062698A1/en not_active Ceased
- 2011-11-07 EA EA201300550A patent/EA026712B1/ru not_active IP Right Cessation
- 2011-11-07 RS RS20250115A patent/RS66479B1/sr unknown
- 2011-11-07 SG SG2013024849A patent/SG189249A1/en unknown
- 2011-11-07 AR ARP110104151A patent/AR083787A1/es unknown
2013
- 2013-04-07 IL IL225597A patent/IL225597A0/en unknown
- 2013-04-22 CL CL2013001104A patent/CL2013001104A1/es unknown
- 2013-05-02 MA MA35865A patent/MA34640B1/fr unknown
- 2013-05-08 CO CO13115446A patent/CO6781465A2/es not_active Application Discontinuation
- 2013-06-04 EC ECSP13012661 patent/ECSP13012661A/es unknown
2014
- 2014-01-17 US US14/157,678 patent/US20140256624A1/en not_active Abandoned
2015
- 2015-05-15 JP JP2015100121A patent/JP6141907B2/ja active Active
2017
- 2017-02-06 JP JP2017019822A patent/JP6515121B2/ja active Active
2018
- 2018-03-08 US US15/915,396 patent/US20180193427A1/en not_active Abandoned
- 2018-04-06 PH PH12018500767A patent/PH12018500767A1/en unknown
2020
- 2020-03-18 US US16/822,360 patent/US20200397867A1/en not_active Abandoned
2021
- 2021-08-12 US US17/400,221 patent/US20220152159A1/en not_active Abandoned
2024
- 2024-06-18 US US18/746,567 patent/US20240335514A1/en active Pending

Also Published As

Publication number	Publication date
RS66479B1 (sr)	2025-03-31
ES3012504T3 (en)	2025-04-09
CA2813661A1 (en)	2012-05-18
EP3539540B1 (en)	2024-12-18
PH12013500809A1 (en)	2019-10-07
JP2013541576A (ja)	2013-11-14
JP6141907B2 (ja)	2017-06-07
EA026712B1 (ru)	2017-05-31
US20180193427A1 (en)	2018-07-12
US20240335514A1 (en)	2024-10-10
AR083787A1 (es)	2013-03-20
MX374694B (es)	2025-03-06
NZ608829A (en)	2015-08-28
EP2637648A1 (en)	2013-09-18
CO6781465A2 (es)	2013-10-31
AU2011328231A1 (en)	2013-04-18
CL2013001104A1 (es)	2013-08-23
WO2012062698A1 (en)	2012-05-18
HRP20250096T1 (hr)	2025-03-28
AP2013006813A0 (en)	2013-04-30
MA34640B1 (fr)	2013-11-02
CN103282030A (zh)	2013-09-04
EA201300550A1 (ru)	2014-02-28
PH12018500767A1 (en)	2019-03-25
PL3539540T3 (pl)	2025-04-14
MX2013005095A (es)	2013-07-05
LT3539540T (lt)	2025-01-10
JP2015143285A (ja)	2015-08-06
HUE070541T2 (hu)	2025-06-28
US20200397867A1 (en)	2020-12-24
KR20190134820A (ko)	2019-12-04
US20220152159A1 (en)	2022-05-19
CA2813661C (en)	2020-06-02
KR102232451B1 (ko)	2021-03-26
KR20130125365A (ko)	2013-11-18
JP2017075196A (ja)	2017-04-20
ECSP13012661A (es)	2013-08-30
DK3539540T3 (da)	2025-02-17
JP6515121B2 (ja)	2019-05-15
PE20140244A1 (es)	2014-03-09
AU2011328231B2 (en)	2015-09-17
CN106177957A (zh)	2016-12-07
BR112013011968A2 (pt)	2016-08-30
SG189249A1 (en)	2013-06-28
MX356491B (es)	2018-05-31
EP3539540A1 (en)	2019-09-18
FI3539540T3 (fi)	2025-01-21
IL225597A0 (en)	2013-06-27
KR102051285B1 (ko)	2019-12-17
US20120283169A1 (en)	2012-11-08
US20140256624A1 (en)	2014-09-11
KR20180095100A (ko)	2018-08-24

Publication	Publication Date	Title
SI3539540T1 (sl)	2025-03-31	Inhibitor SGLT2 1-kloro-4-(beta-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran- 3-iloksi)-benzil]-benzen v kombinaciji z insulinom za uporabo pri postopku za zmanjšanje tveganja hipoglikemije
GB2470483B (en)	2014-06-04	Improvements in the management of medical tubing
ZA201200224B (en)	2012-09-26	Long acting insulin composition
GB2511657B (en)	2014-12-31	Fracture monitoring
EP2443553A4 (en)	2012-12-19	ANNOTATION OF VIRTUAL APPLICATION PROCESS
PT2389212T (pt)	2018-02-07	Seringa
ZA201204050B (en)	2013-02-27	Vaccination syringe
ZA201204343B (en)	2014-01-29	Adaptable medical workflow system
GB0918228D0 (en)	2009-12-02	Heatable glazing
SG10201400931RA (en)	2014-07-30	Agent for enhancing hypoglycemic activity
IL215265A0 (en)	2011-11-30	Syringe for single use
GB0821249D0 (en)	2008-12-31	Finger razor
EP2416010A4 (en)	2014-12-17	SYRINGE DRIVE UNIT
ZA201007982B (en)	2012-06-27	Gear pumps and methods for using gear pumps
GB0812019D0 (en)	2008-08-06	Insulin
EP2260106A4 (en)	2011-04-20	IMPROVED BETATHYMOSINFRAGMENTS
EP2455090A4 (en)	2013-01-02	MEANS TO INHIBIT THE INCREASE OF THE POSTPRANDIAL BLOOD INSULIN MIRROR
GB0908425D0 (en)	2009-06-24	Medical use
GB0912665D0 (en)	2009-08-26	Force-transmitting element for use in medical catheters
PL2103321T3 (pl)	2013-04-30	Strzykawka jednorazowego użytku
GB0909081D0 (en)	2009-07-01	Free hand suction syringe
EP2664338A4 (en)	2014-07-09	HEMMER FOR INCREASING THE BLOOD GIP MIRROR, HEMMER FOR INCREASING THE BLOOD OF THE INSULIN MIRROR, MEANS FOR REDUCING THE POSTPRANDIAL TRIGLYCERID MIRROR AND HEMMER FOR INCREASING THE BLOOD SUGAR MIRROR
GB0922316D0 (en)	2010-02-03	Syringe
TWM369752U (en)	2009-12-01	Surgical blade structure for curing trigger finger
HU0900507D0 (en)	2009-10-28	Activating tube for skin regenerating